Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice

International Clinical Psychopharmacology

Volumn 11, Issue 2, 1996, Pages 129-136

  Patris, M ^a   Bouchard, J M ^b   Bougerol, T ^c   Charbonnier, J F ^d   Chevalier, J F ^e   Clerc, G ^f   Cyran, C ^g   Van Amerongen, P ^h   Lemming, O ⁱ   Hopfner Petersen H E ⁱ  

^a HÔPITAL CIVIL   (France)

^b Hôpital Gérard Marchant   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d Hopital Saint Jacques Clermont Ferrand   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f Centre Hospitalier Specialise   (France)

^g Centre Hospitalier de LENS   (France)

^h CENTRE HOSPITALIER INTERCOMMUNAL   (France)

ⁱ H LUNDBECK A S   (Denmark)

Author keywords

Citalopram; Clinical study; Depression; Fluoxetine; General practice; SSRIs

Indexed keywords

CITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 8944259904     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199606000-00007     Document Type: Article

References (24)

1. Altamura AC, Montgomery SA and Wernicke JF (1988) The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry, 153 (suppl 3), 109-112.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn rev) (DSM-III-R). Washington DC: APA.
3. Benfield P, Heel RC and Lewis SP (1986) Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs, 32, 481-508.
4. Bech P and Cialdella P (1992) Citalopram in depression - meta-analysis of intended and unintended effects. International Clinical Psychopharmacology, 6 (suppl 5), 45-54.
5. Bouchard J-M, Delaunay J, Delisle J-P et al. (1987) Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatrica Scandinavica, 76, 583-592.
6. CPMP Guidelines (1989) Clinical evaluation of antidepressant drugs Doc: 111/476/87, Rev. 7, Circular 2825, January.
7. Danish University Antidepressant Group (DUAG) (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology, 90, 131-138.
8. Dencker SJ and Høpfner Petersen HE (1989) Side-effect profile of citalopram and reference antidepressants in depression. In: Citalopram. The New Antidepressant from Lundbeck Research (Ed. SA Montgomery), pp. 31-42. Excerpta Medica, Amsterdam, The Netherlands.
9. De Wilde J, Mertens C, Fredricson Overø K and Høpfner Petersen HE (1985) Citalopram versus mianserin: a controlled, double-blind trial in depressed patients. Acta Psychiatrica Scandinavica, 72, 89-96.
10. Gravem A, Amthor KF, Astrup C, et al. (1987) A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatrica Scandinavica, 75, 478-486.
11. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No. (ADM) National Institute of Mental Health, Rockville, Maryland, USA, 76, 217-222.
12. Hamilton M (1960) A rating scale for depression. Journal of Neurology and Neurosurgical Psychiatry, 76, 56-62.
13. Hyttel J (1982) Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress of Neuro-Psychopharmacology and Biological Psychiatry, 6, 277-295.
14. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 9 (suppl 1), 19-26.
15. Mendels J, Fabre L and Kiev A (1990) A double-blind placebo controlled study of citalopram in major depressive disorder. Presented at the Annual NCDEU Meeting in Key Biscayne.
16. Milne RJ and Goa KL (1991) Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs, 41, 450-477.
17. Montgomery SA and Åsberg M (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
18. Montgomery SA, Rasmussen JGC, Lyby K, et al. (1992) Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. International Clinical Psychopharmacology, 6 (suppl 5), 65-70.
19. Montgomery SA, Pedersen V, Tanghøj P, et al. (1994) The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. International Clinical Psychopharmacology, 9 (suppl 1), 35-40.
20. Quitkin FM, Rabkin JG, Ross D, et al. (1984) Duration of antidepressant drug treatment. What is an adequate trial? Archives of General Psychiatry, 41, 238-245.
21. Rosenberg C, Damsbo N, Fuglum E, et al. (1994) Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre, clinical study. International Clinical Psychopharmacology, 9 (suppl 3), 41-48.
22. Schiurmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmocokinetics and Biopharmaceutics, 15, 657-680.
23. Shaw D, Thomas DR, Briscoe MH, et al. (1986) A comparison of the antidepressant action of citalopram and amitriptyline. British Journal of Psychiatry, 149, 515-517.
24. Wernicke JF, Dunlop SR, Dornsief BE, et al. (1987) Fixed-dose fluoxetine therapy for depression. Psychopharmacology Bulletin, 23, 164-167.